
    
      A randomized, phase II trial designed to evaluate the progression free survival in patients
      with metastatic pancreatic cancer on triplet therapy (nab-paclitaxel + gemcitabine +
      cisplatin) while on ketogenic diet or non-ketogenic diet. This study also aims to compare the
      changes in serum metabolites and quality of life between the two arms.
    
  